Ikena Oncology Announces Strategic Update
Ikena Oncology, Inc. (IKNA)
Company Research
Source: GlobeNewswire
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development of IK-595, a novel MEK-RAF molecular glue. Concurrently, Ikena is evaluating strategic options for both the Company and its development pipeline. “Ikena is dedicated to thoughtfully putting our capital to work towards impactful treatments for patients, and in doing so building value for our shareholders. Together with our board of directors, we made the difficult decision to wind down the IK-930 program. Going forward, we believe that IK-930’s profile may enable combination opportunitie
Show less
Read more
Impact Snapshot
Event Time:
IKNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IKNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IKNA alerts
High impacting Ikena Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
IKNA
News
- It's Unlikely That Ikena Oncology, Inc.'s (NASDAQ:IKNA) CEO Will See A Huge Pay Rise This Year [Yahoo! Finance]Yahoo! Finance
- Ikena Oncology, Inc. (NASDAQ: IKNA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $2.00 price target on the stock, down previously from $8.00.MarketBeat
- Ikena Oncology, Inc. (NASDAQ: IKNA) had its price target lowered by analysts at HC Wainwright from $11.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- UPDATE – Ikena Oncology Announces Strategic UpdateGlobeNewswire
- Ikena Oncology Announces Strategic Update [Yahoo! Finance]Yahoo! Finance
IKNA
Earnings
- 3/12/24 - In-Line
IKNA
Sec Filings
- 6/10/24 - Form 4
- 6/10/24 - Form 4
- 6/10/24 - Form 4
- IKNA's page on the SEC website